EUVIMEDEUVIMED entdecken
Crossref

Trends in the Use of Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Heart Transplant Patients in Virginia

Michael Mazzeffi, Jared Beller, Raymond Strobel, Anthony Norman, Alexander Wisniewski, Judy Smith, Clifford E Fonner, John McNeil, Alan Speir, Ramesh Singh, Daniel Tang, Mohammed Quader und 2 weitere

Journal of Cardiothoracic and Vascular Anesthesia · 2024

DOI: 10.1053/j.jvca.2023.10.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiothoracic and Vascular Anesthesia, 2024. Verfasst von Michael Mazzeffi und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Virginia, Department of Anesthesiology, Charlottesville, VA. Electronic address: mmazzeff@uvahealth.org. Hauptthemen laut MEDLINE: Heart Transplantation, Thrombosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To explore trends in intraoperative procoagulant factor concentrate use in patients undergoing heart transplantation (HTx) in Virginia. Secondarily, to evaluate their association with postoperative thrombosis. DESIGN: Patients who underwent HTx were identified using a statewide database. Trends in off-label recombinant activated factor VII (rFVIIa) use and on-label and off-label prothrombin complex concentrate (PCC) use were tested using the Mantel-Haenszel test. Multivariate logistic regression was used to test for an association between procoagulant factor concentrate administration and thrombosis. SETTING: Virginia hospitals performing HTx. PARTICIPANTS: Adults undergoing HTx between 2012 and 2022. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Among 899 patients who required HTx, 100 (11.1%) received off-label rFVIIa, 69 (7.7%) received on-label PCC, and 80 (8.9%) received off-label PCC. There was a downward trend in the use of rFVIIa over the 10-year period (p = 0.04). There was no trend in on-label PCC use (p = 0.12); however, there was an increase in off-label PCC use (p < 0.001). Patients who received rFVIIa were transfused more and had longer cardiopulmonary bypass time (p < 0.001). Receipt of rFVIIa was associated with increased thrombotic risk (odds ratio [OR] 1.92; 95% CI 1.12-3.29; p = 0.02), whereas on-label and off-label PCC use had no association with thrombosis (OR 0.98, 95% CI 0.49-1.96, p = 0.96 for on-label use; and OR 0.61, 95% CI 0.29-1.30, p = 0.20 for off-label use). CONCLUSIONS: Use of rFVIIa in HTx decreased over the past decade, whereas off-label PCC use increased. Receipt of rFVIIa was associated with thrombosis; however, patients who received rFVIIa were more severely ill, and risk adjustment may have been incomplete.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart TransplantationThrombosisAdultHumansBlood Coagulation FactorsFactor IXFactor VIIaRecombinant ProteinsRetrospective StudiesVirginia

Stichwörter der Autor:innen

bleedingcoagulationheart transplantthrombosis

Substanzen

Blood Coagulation FactorsFactor IXFactor VIIaprothrombin complex concentratesrecombinant FVIIaRecombinant Proteins

Autor:innen und Institutionen

  • University of Virginia, Department of Anesthesiology, Charlottesville, VA. Electronic address: mmazzeff@uvahealth.org.
  • University of Virginia, Department of Surgery, Division of Cardiothoracic Surgery, Charlottesville, VA.
  • Virginia Cardiac Surgery Quality Initiative, South Riding, VA.
  • University of Virginia, Department of Anesthesiology, Charlottesville, VA.
  • INOVA Heart and Vascular Institute, Department of Cardiothoracic Surgery, Fairfax, VA.
  • Virginia Commonwealth University, Department of Surgery, Division of Cardiothoracic Surgery, Richmond, VA.

Förderung

  • National Heart, Lung, and Blood Institute

Zitieren

APA

Mazzeffi, M., Beller, J., Strobel, R., Norman, A., Wisniewski, A., Smith, J., Fonner, C. E., McNeil, J., Speir, A., Singh, R., Tang, D., Quader, M., Yarboro, L., & Teman, N. (2024). Trends in the Use of Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Heart Transplant Patients in Virginia. Journal of Cardiothoracic and Vascular Anesthesia. https://doi.org/10.1053/j.jvca.2023.10.003

Vancouver

Mazzeffi M, Beller J, Strobel R, Norman A, Wisniewski A, Smith J, et al. Trends in the Use of Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Heart Transplant Patients in Virginia. Journal of Cardiothoracic and Vascular Anesthesia. 2024. doi:10.1053/j.jvca.2023.10.003

BibTeX
@article{Mazzeffi2024,
  author = {Mazzeffi, Michael and Beller, Jared and Strobel, Raymond and Norman, Anthony and Wisniewski, Alexander and Smith, Judy and Fonner, Clifford E and McNeil, John and Speir, Alan and Singh, Ramesh and Tang, Daniel and Quader, Mohammed and Yarboro, Leora and Teman, Nicholas},
  title = {Trends in the Use of Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Heart Transplant Patients in Virginia},
  journal = {Journal of Cardiothoracic and Vascular Anesthesia},
  year = {2024},
  doi = {10.1053/j.jvca.2023.10.003}
}
Kostenlos starten →